Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06463028 · ClinicalTrials.gov registry record · Phase 2

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

A Phase 2 study of Endometrial Cancer, sponsored by Faeth Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
18
Study locations

NCT06463028 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Faeth Therapeutics. The registered enrollment target is 40 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06463028, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Faeth Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
18
Study locations

Study Summary

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG Sapanisertib
  • DRUG Serabelisib

Study Locations (18)

Florida

  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Florida Cancer Specialists, North - St. Petersburg
  • Florida Cancer Specialists, East - West Palm Beach

California

  • UC San Diego Moores Cancer Center - La Jolla
  • University of California, San Francisco (UCSF) - San Francisco

New York

  • Women's Cancer Care Associates, LLC - Albany
  • Memorial Sloan Kettering Cancer Center - New York

Oregon

  • Oncology Associates of Oregon, P.C. - Eugene
  • Northwest Cancer Specialists, P.C. - Portland

Pennsylvania

  • Alliance Cancer Specialists, PC - Doylestown
  • West Penn Hospital - Pittsburgh

Texas

  • Texas Oncology - West Texas - El Paso
  • Texas Oncology - Gulf Coast - The Woodlands

Maryland

  • Maryland Oncology Hematology, P.A. - Brandywine

Minnesota

  • Minnesota Oncology Hematology, P.A. - Maple Grove

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-12-12
Est. Completion 2029-09
Phase Phase 2

Sponsor

Faeth Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06463028

The ClinicalTrials.gov registry entry for NCT06463028 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Faeth Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Paclitaxel is the first listed.

NCT06463028 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT06463028 about?

NCT06463028 is a clinical study titled "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer". This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

What is the current status of trial NCT06463028?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-12-12. Estimated completion is 2029-09.

What conditions does trial NCT06463028 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT06463028?

The interventions under investigation include: Paclitaxel (DRUG), Sapanisertib (DRUG), Serabelisib (DRUG).

Who is sponsoring clinical trial NCT06463028?

This trial is sponsored by Faeth Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06463028 being conducted?

This trial has 18 study locations across California, Florida, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.